1. |
Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J, 2014, 35(42): 2950-2959.
|
2. |
《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告 2020》要点解读. 中国心血管杂志, 2021, 26(3): 209-218.
|
3. |
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 2000, 35(3): 569-582.
|
4. |
Sutton NR, Li S, Thomas L, et al. The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database. Am Heart J, 2016, 178: 65-73.
|
5. |
Segev A, Strauss BH, Tan M, et al. Prognostic significance of admission heart failure in patients with non-ST-elevation acute coronary syndromes (from the Canadian Acute Coronary Syndrome Registries). Am J Cardiol, 2006, 98(4): 470-473.
|
6. |
Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation, 2004, 109(4): 494-499.
|
7. |
Juillière Y, Cambou JP, Bataille V, et al. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Rev Esp Cardiol (Engl Ed), 2012, 65(4): 326-333.
|
8. |
Ndrepepa G, Mehilli J, Martinoff S, et al. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol, 2007, 50(2): 149-156.
|
9. |
Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med, 2006, 355(12): 1210-1221.
|
10. |
Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Glob Heart, 2012, 7(4): 275-295.
|
11. |
Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol, 1967, 20(4): 457-464.
|
12. |
Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J, 2005, 149(1): 67-73.
|
13. |
Bagnall AJ, Goodman SG, Fox KA, et al. Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol, 2009, 103(11): 1530-1536.
|
14. |
Alabas OA, Allan V, McLenachan JM, et al. Age-dependent improvements in survival after hospitalisation with acute myocardial infarction: an analysis of the Myocardial Ischemia National Audit Project (MINAP). Age Ageing, 2014, 43(6): 779-785.
|
15. |
Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol, 2011, 8(1): 30-41.
|
16. |
Nesković AN, Otasević P, Bojić M, et al. Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification. Am Heart J, 1999, 137(2): 361-367.
|
17. |
Khot UN, Jia G, Moliterno DJ, et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. JAMA, 2003, 290(16): 2174-2181.
|
18. |
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation, 2000, 101(25): 2981-2988.
|
19. |
Francis Stuart SD, De Jesus NM, Lindsey ML, et al. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol, 2016, 91: 114-122.
|
20. |
DeGeare VS, Boura JA, Grines LL, et al. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol, 2001, 87(9): 1035-1038.
|
21. |
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001, 357(9266): 1385-1390.
|
22. |
Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA, 2001, 285(4): 430-436.
|
23. |
Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol, 1997, 29: 1060-1066.
|
24. |
Lewinter C, Bland JM, Crouch S, et al. Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. Eur J Heart Fail, 2014, 16(1): 95-102.
|
25. |
Baehr A, Hinkel R, Kupatt C. Statins make a difference in acute myocardial infarction: a revival. J Am Coll Cardiol, 2020, 75(12): 1403-1405.
|
26. |
Coleman EA, Smith JD, Raha D, et al. Posthospital medication discrepancies: prevalence and contributing factors. Arch Intern Med, 2005, 165(16): 1842-1847.
|
27. |
Østergaard K, Hallas J, Bak S, et al. Long-term use of antiplatelet drugs by stroke patients: a follow-up study based on prescription register data. Eur J Clin Pharmacol, 2012, 68(12): 1631-1637.
|
28. |
Shahabi V, Moazenzadeh M, Azimzadeh BS, et al. Relationship between serum N-terminal pro brain natriuretic peptide (NT-Pro BNP) level and the severity of coronary artery involvements. J Res Med Sci, 2011, 16(2): 143-148.
|
29. |
Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev, 2007, 12(1): 23-36.
|
30. |
O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013, 127(4): e362-425.
|
31. |
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64(24): e139-e228.
|
32. |
Kochar A, Al-Khalidi HR, Hansen SM, et al. Delays in primary percutaneous coronary intervention in ST-segment elevation myocardial infarction patients presenting with cardiogenic shock. JACC Cardiovasc Interv, 2018, 11(18): 1824-1833.
|
33. |
van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation, 2017, 136(16): e232-e268.
|
34. |
Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med, 2003, 163(19): 2345-2353.
|
35. |
Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000, 284(7): 835-842.
|
36. |
Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early Ⅱ trial substudy. Circulation, 2000, 102(17): 2031-2037.
|